Drug Trial Radar · NCT04821102
Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration
Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
21
Planned (sponsor's estimate)
Start
Jul 1, 2023
Primary completion
Aug 1, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- R-BioIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm cartilage regeneration through arthroscopy after a single administration of autologous Adipose Tissue derived Mesenchymal stem cells(JOINTSTEM) in patients with degenerative arthritis of K-L grade 3
Conditions
- Degenerative Arthritis
- Knee Arthritis
Interventions
JOINTSTEMBiological
JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
SalineDrug
saline, 1 time injection under ultrasonic guided
Primary outcomes
What the sponsor says the trial is designed to measure.
- ArthroscopyTime frame: 48 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bethesda Hospital
Yangsan, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.